Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DB26FY18V
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,569
Award facts
- Contract value 100% obligated
- $18,568.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,568.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The delivery order, issued on October 23, 2025, with an ultimate completion date of November 14, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform this work at its Park Ridge facility and deliver the pharmaceutical product to support Department of Defense medical supply needs.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, authorizing DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, biologics, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous recent delivery orders demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FY18V?
SPE2DB26FY18V was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FY18V worth?
The government has obligated $18,569 on SPE2DB26FY18V.
Is contract SPE2DB26FY18V an order under another contract?
Yes. SPE2DB26FY18V is a delivery order under SPE2DB22D9362, an indefinite delivery contract.
Was contract SPE2DB26FY18V competed?
The extent of competition for SPE2DB26FY18V was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award